Mandate

Vinge advises IRLAB Therapeutics in connection with share issues

December 13, 2019 Capital Markets and Public M&A

Vinge advises IRLAB Therapeutics in connection with a directed share issue of SEK 70 million and a rights issue of approximately SEK 145 million.

The directed share issue was subscribed for by a number of institutional and qualified investors on the basis of an accelerated book building process. The rights issue is expected to be completed during the first quarter of 2020.

IRLAB Therapeutics is a research and development company, listed on Nasdaq First North Premier Growth Market, focused on development of novel therapies for the treatment of neurodegenerative diseases, in particular Parkinson’s disease and dementia.

Vinge’s team has consisted of Dain Hård Nevonen, Nils Fredrik Dehlin, Stephanie Stiernstedt, Stojan Arnerstål, Anna Thoms and Maria Schultzberg.

Related

Vinge advises Axcel and Accru Partners in connection with the acquisitions of Baker Tilly Helsingborg AB, MOORE Allegretto AB and MOORE Ranby AB

Vinge has advised Axcel VII and Accru Partners in connection with the acquisitions of Baker Tilly Helsingborg AB, MOORE Allegretto AB and MOORE Ranby AB.
September 18, 2025

Vinge advises Workday, Inc. on its $1.1 billion acquisition of Sana Labs

Vinge, together with Orrick Herrington & Sutcliffe, has advised Workday, Inc. (NASDAQ: WDAY) (“Workday”) on its acquisition of all shares in Sana Labs AB.
September 16, 2025

Vinge advises on the sale of ArmaTech to Defensor Group

Vinge has advised on the sale of ArmaTech i Kungsbacka AB (“ArmaTech”) to the newly formed defence group Defensor Group AB (“Defensor”).
September 16, 2025